|
|
News Breaks | | | | November 29, 2012 | | 19:08 EDT |  | ALIM | Alimera's Iluvien receives final draft guidance from U.K.'s NICE
Alimera Sciences announced that the United Kingdom's National Institute for Health and Clinical Excellence, or NICE, has issued final draft guidance indicating that Iluvien is not recommended for the treatment of chronic diabetic macular edema, or DME, considered insufficiently responsive to available therapies. While the Appraisal Committee acknowledged the clinical effectiveness of Iluvien in the treatment of vision impairment associated with chronic DME considered insufficiently responsive to available therapies, it noted that cost-effectiveness thresholds for the product have not yet been met. In response to the final draft guidance, Alimera is now developing a Patient Access Scheme, or PAS, to address the Appraisal Committee's cost concerns that pose a barrier to access for people in the United Kingdom with chronic DME who might benefit from Iluvien. The goal of the PAS will be to determine the appropriate pricing for Iluvien in order to ensure that treatment decisions are based on patient need, rather than cost. | |
|
News For ALIM From The Last 14 Days Check below for free stories on ALIM the last two weeks. |
|
|
| May 14, 2013 | | 12:00 EDT |  | ALIM | Alimera Sciences rises 16.4%
Alimera Sciences is up 16.4%, or 65c, to $4.61 | | | May 9, 2013 | | 16:30 EDT |  | ALIM | Alimera Sciences reports Q1 EPS (27c) , consensus (27c)
| | | May 7, 2013 | | 16:39 EDT | | ALIM | pSivida announces commercial launch of Iluvien in Germany
 Subscribe for More Information | | | 16:21 EDT | | ALIM | Alimera Sciences announces first patient treated with Iluvien
Subscribe for More Information | |
|
|
|
|
|
|
